Table 2. PSM-adjusted hospital-acquired complications and adverse PE events among LRPE patients with long versus short LOS during the 90-day follow-up period.
| Long LOS | Short LOS (≤2 days) Cohort | 95% Wald Confidence Limits* | ||||
|---|---|---|---|---|---|---|
| (≥2 days) Cohort | ||||||
| N = (392) | N = (392) | |||||
| N/Mean | %/SD | N/Mean | %/SD | |||
| Hospital-acquired Complications during Index Hospitalization | ||||||
| Hospital-acquired complications, any | 52 | 13.3% | 6 | 1.5% | 3.77 | 19.94 |
| Catheter-associated urinary tract Infection | 2 | 0.5% | 0 | 0.0% | ||
| Methicillin-resistant staphylococcus aureus | 5 | 1.3% | 1 | 0.3% | 0.59 | 42.60 |
| Clostridium difficile infection | 3 | 0.8% | 0 | 0.0% | ||
| Hospital-acquired (bacterial) pneumonia | 33 | 8.4% | 0 | 0.0% | ||
| Foreign object retained after surgery | 1 | 0.3% | 0 | 0.0% | ||
| Pressure ulcer stages III & IV | 1 | 0.3% | 0 | 0.0% | ||
| Trauma/injury | 13 | 3.3% | 5 | 1.3% | 0.94 | 7.22 |
| Vascular catheter-associated infection | 1 | 0.3% | 0 | 0.0% | ||
| Surgical site infection | 1 | 0.3% | 0 | 0.0% | ||
| Bacterial pneumonia | 46 | 11.7% | 23 | 5.9% | 1.24 | 3.23 |
| 90-day Adverse PE Events | ||||||
| Recurrent VTE | 14 | 3.6% | 13 | 3.3% | 0.51 | 2.26 |
| Time to first VTE, days | 34.6 | 26.7 | 34 | 18.3 | -17.70 | 18.84 |
| Major Bleeding | 5 | 1.3% | 4 | 1.0% | 0.34 | 4.62 |
| Time to first Major Bleeding, days | 22.4 | 21.3 | 37 | 29.4 | -54.42 | 25.22 |
| Death | 10 | 2.6% | 10 | 2.6% | 0.42 | 2.38 |
| Time to Death, days | 30.9 | 23.6 | 40.5 | 24 | -31.99 | 12.79 |
| Net Clinical Benefit (1- [any hospital acquired complication or adverse PE events] | 307 | 78.3% | 341 | 86.9% | 0.84 | 0.96 |
* CI cannot be calculated if any one of the cohorts had 0.00% HAC's
PE: pulmonary embolism; PSM: propensity score matching; SD: Standard Deviation; VTE: venous thromboembolism